Keywords
neoplasms metastasis
neoplasms, radiation-induced
radiotherapy
risk assessment
survival
References
Lievens Y, Borras JM, Grau C. Provision and use of radiothera-py in Europe. Mol Oncol 2020l; 14(7): 1461‒9.
Dracham CB, Shankar A, Madan R. Radiation-induced second-ary malignancies: a review article. Radiat Oncol J 2018; 36(2): 85‒94.
Cahan WG, Woodard HQ, Higinbotham NL, Stewart FW, Coley BL. Sarcoma arising in irradiated bone: report of eleven cases. 1948. Cancer 1998; 82(1): 8‒34.
Singh GK, Yadav V, Singh P, Bhowmik KT. Radiation-Induced Malignancies Making Radiotherapy a "Two-Edged Sword": A Review of Literature. World J Oncol 2017; 8(1): 1‒6.
Zheng X, Li X, Wang M, Shen J, Sisti G, He Z, et al. Multidis-ciplinary Oncology Research Collaborative Group (MORCG). Second primary malignancies among cancer patients. Ann Transl Med 2020; 8(10): 638.
Zwicker F, Kirchner C, Huber PE, Debus J, Zwicker H, Klepper R. Breast cancer occurrence after low dose radiotherapy of non-malignant disorders of the shoulder. Sci Rep 2019; 9(1): 5301.
Meadows A, Friedman D, Neglia J, Mertens A, Sarah S. Donaldson S, et al. Second Neoplasms in Survivors of Childhood Cancer: Findings from the Childhood Cancer Survivor Study Cohort. J Clin Oncol 2009; 27(14): 2356–62.
Zakaria D, Shaw A, Xie L. Risk of a second cancer in Canadi-ans diagnosed with a first cancer in childhood or adolescence. EClinicalMedicine 2019; 16: 107–20.
Kumar S. Second malignant neoplasms following radiotherapy. Int J Environ Res Public Health 2012; 9(12): 4744‒59.
Armstrong GT, Sklar CA, Hudson MM, Robison LL. Long-term health status among survivors of childhood cancer: does sex matter? J Clin Oncol 2007; 25(28): 4477‒89.
Cooke R, Jones ME, Cunningham D, Falk SJ, Gilson D, Hancock BW, et al. Breast cancer risk following Hodgkin lymphoma ra-diotherapy in relation to menstrual and reproductive factors. Br J Cancer 2013; 108(11): 2399‒406.
Schneider U, Sumila M, Robotka J. Site-specific dose-response relationships for cancer induction from the combined Japanese A-bomb and Hodgkin cohorts for doses relevant to radiother-apy. Theor Biol Med Model 2011; 8: 27.
Teepen JC, van Leeuwen FE, Tissing WJ, van Dulmen-den Broeder E, van den Heuvel-Eibrink MM, van der Pal HJ, et al. Long-Term Risk of Subsequent Malignant Neoplasms After Treatment of Childhood Cancer in the DCOG LATER Study Cohort: Role of Chemotherapy. J Clin Oncol 2017; 35(20): 2288‒98.
Bassal M, Mertens AC, Taylor L, Neglia JP, Greffe BS, Hammond S, et al. Risk of selected subsequent carcinomas in survivors of childhood cancer: a report from the Childhood Cancer Survi-vor Study. J Clin Oncol 2006; 24(3): 476‒83.
Fung C, Fossa SD, Milano MT, Oldenburg J, Travis LB. Solid tumors after chemotherapy or surgery for testicular nonsemi-noma: a population-based study. J Clin Oncol 2013; 31(30): 3807‒14.
Tiruneh T, Enawgaw B, Shiferaw E. Genetic Pathway in the Pathogenesis of Therapy-Related Myeloid Neoplasms: A Lit-erature Review. Oncol Ther 2020; 8(1): 45‒57.
Brenner DJ, Doll R, Goodhead DT, Hall EJ, Land CE, Little JB, et al. Cancer risks attributable to low doses of ionizing radia-tion: assessing what we really know. Proc Natl Acad Sci U S A 2003; 100(24): 13761‒6.
Salminen SH, Sampo MM, Böhling TO, Tuomikoski L, Tarkkanen M, Blomqvist CP. Radiation-associated sarcoma after breast cancer in a nationwide population: Increasing risk of angiosar-coma. Cancer Med 2018; 7(9): 4825‒35.
Cohen-Hallaleh RB, Smith HG, Smith RC, Stamp GF, Al-Muderis O, Thway K, et al. Radiation induced angiosarcoma of the breast: outcomes from a retrospective case series. Clin Sar-coma Res 2017; 7: 15.
Grantzau T, Overgaard J. Risk of second non-breast cancer after radiotherapy for breast cancer: a systematic review and meta-analysis of 762,468 patients. Radiother Oncol 2015; 114(1): 56‒65.
Berrington de Gonzalez A, Curtis RE, Gilbert E, Berg CD, Smith SA, Stovall M, et al. Second solid cancers after radiotherapy for breast cancer in SEER cancer registries. Br J Cancer 2010; 102(1): 220‒6.
Mladenovic J, Susnjar S, Tanic M, Jankovic R, Karadzic K, Gavrilo-vic D, et al. Tumor response and patient outcome after pre-operative radiotherapy in locally advanced non-inflammatory breast cancer patients. J BUON 2017; 22(2): 325‒33.
Fontenot JD, Lee AK, Newhauser WD. Risk of secondary malig-nant neoplasms from proton therapy and intensity-modulated X-ray therapy for early-stage prostate cancer. Int J Radiat On-col Biol Phys 2009; 74(2): 616–22.
Brenner DJ, Curtis RE, Hall EJ, Ron E. Second malignancies in prostate carcinoma patients after radiotherapy compared with surgery. Cancer 2000; 88(2): 398‒406.
Chaturvedi AK, Engels EA, Gilbert ES, Chen BE, Storm H, Lynch CF, et al. Second cancers among 104,760 survivors of cervical cancer: evaluation of long-term risk. J Natl Cancer Inst 2007; 99(21): 1634‒43.
Rodriguez AM, Kuo YF, Goodwin JS. Risk of colorectal cancer among long-term cervical cancer survivors. Med Oncol 2014; 31(5): 943.
Creutzberg CL, Nout RA, Lybeert ML, Wárlám-Rodenhuis CC, Jobsen JJ, Mens JW, et al. Fifteen-year radiotherapy outcomes of the randomized PORTEC-1 trial for endometrial carcino-ma. Int J Radiat Oncol Biol Phys 2011; 81(4): e631‒8.
Hodgson DC, Gilbert ES, Dores GM, Schonfeld SJ, Lynch CF, Storm H, et al. Long-Term Solid Cancer Risk Among 5-Year Survivors of Hodgkin’s Lymphoma. J Clin Oncol 2007; 25(12): 1489‒97.
Tward JD, Wendland MM, Shrieve DC, Szabo A, Gaffney DK. The risk of secondary malignancies over 30 years after the treatment of non-Hodgkin lymphoma. Cancer 2006; 107(1): 108‒15.
Friedman DL, Whitton J, Leisenring W, Mertens AC, Hammond S, Stovall M, et al. Subsequent neoplasms in 5-year survivors of childhood cancer: the Childhood Cancer Survivor Study. J Natl Cancer Inst 2010; 102(14): 1083‒95.
Robison LL, Hudson MM. Survivors of childhood and adoles-cent cancer: life-long risks and responsibilities. Nat Rev Can-cer 2014; 14(1): 61‒70.
Bergom C, West CM, Higginson DS, Abazeed ME, Arun B, Bentzen SM, et al. The Implications of Genetic Testing on Ra-diation Therapy Decisions: A Guide for Radiation Oncolo-gists. Int J Radiat Oncol Biol Phys 2019; 105(4): 698‒712.
Burt LM, Ying J, Poppe MM, Suneja G, Gaffney DK. Risk of sec-ondary malignancies after radiation therapy for breast cancer: Comprehensive results. Breast 2017; 35: 122‒9.
Kleinerman RA. Radiation-sensitive genetically susceptible pe-diatric sub-populations. Pediatr Radiol 2009; 39(Suppl 1): S27‒31.
Dong L, Cui J, Tang F, Cong X, Han F. Ataxia telangiectasia-mutated gene polymorphisms and acute normal tissue injuries in cancer patients after radiation therapy: a systematic review and meta-analysis. Int J Radiat Oncol Biol Phys 2015; 91(5): 1090‒8.
Huszno J, Budryk M, Kołosza Z, Nowara E. The influence of BRCA1/BRCA2 mutations on toxicity related to chemother-apy and radiotherapy in early breast cancer patients. Oncology 2013; 85(5): 278‒82.
Berrington de Gonzalez A, Curtis RE, Kry SF, Gilbert E, Lamart S, Berg CD, et al. Proportion of second cancers attributable to radiotherapy treatment in adults: a cohort study in the US SEER cancer registries. Lancet Oncol 2011; 12(4): 353‒60.
Tanić M, Krivokuća A, Čavić M, Mladenović J, Plesinac Karapandžić V, Beck S, et al. Molecular signature of response to preopera-tive radiotherapy in locally advanced breast cancer. Radiat Oncol 2018; 13(1): 193.
Best T, Li D, Skol AD, Kirchhoff T, Jackson SA, Yasui Y, et al. Variants at 6q21 implicate PRDM1 in the etiology of therapy-induced second malignancies after Hodgkin's lymphoma. Nat Med 2011; 17(8): 941‒3.
Huang SC, Zhang L, Sung YS, Chen CL, Kao YC, Agaram NP, et al. Recurrent CIC Gene Abnormalities in Angiosarcomas: A Molecular Study of 120 Cases with Concurrent Investigation of PLCG1, KDR, MYC, and FLT4 Gene Alterations. Am J Surg Pathol 2016; 40(5): 645‒55.
Ginter PS, Mosquera JM, MacDonald TY, D'Alfonso TM, Rubin MA, Shin SJ. Diagnostic utility of MYC amplification and an-ti-MYC immunohistochemistry in atypical vascular lesions, primary or radiation-induced mammary angiosarcomas, and primary angiosarcomas of other sites. Hum Pathol 2014; 45(4): 709‒16.
Knopf A, Lempart J, Bas M, Slotta-Huspenina J, Mansour N, Fritsche MK. Oncogenes and tumor suppressor genes in squa-mous cell carcinoma of the tongue in young patients. Onco-target 2015; 6(5): 3443‒51.
Mak RH, Hermann G, Lewis JH, Aerts HJWL, Baldini EH, Chen AB, et al. Outcomes by tumor histology and KRAS mu-tation status after lung stereotactic body radiation therapy for early-stage non-small-cell lung cancer. Clin Lung Cancer 2015; 16(1): 24‒32.
Jackson SP, Bartek J. The DNA-damage response in human biol-ogy and disease. Nature 2009; 461(7267): 1071‒8.
Hall EJ. Cancer caused by x-rays--a random event? Lancet Oncol 2007; 8(5): 369‒70.
Laramore GE. Role of particle radiotherapy in the manage-ment of head and neck cancer. Curr Opin Oncol 2009; 21(3): 224‒31.
Suzuki M, Watanabe M, Suzuki K, Nakano K, Kaneko I. Neo-plastic cell heavy ions. Radiat Res 1989; 120(3): 468‒76.
Brenner DJ, Hall EJ. Secondary neutrons in clinical proton ra-diotherapy: a charged issue. Radiother Oncol 2008; 86(2): 165‒70.
Eaton BR, MacDonald SM, Yock TI, Tarbell NJ. Secondary Ma-lignancy Risk Following Proton Radiation Therapy. Front Oncol 2015; 5: 261.
Chung CS, Yock TI, Nelson K, Xu Y, Keating NL, Tarbell NJ. In-cidence of second malignancies among patients treated with proton versus photon radiation. Int J Radiat Oncol Biol Phys 2013; 87(1): 46‒52.
Marjanovic D, Plesinac Karapandzic V, Stojanovic Rundic S, To-masevic A, Saric M, Miskovic I, et al. Implementation of intensi-ty-modulated radiotherapy and comparison with three-dimensional conformal radiotherapy in the postoperative treatment of cervical cancer. J BUON 2019; 24(5): 2028‒34.
Marjanovic D, Plesinac Karapandzic V, Stojanovic Rundic S, To-masevic A, Saric M, Miskovic I, et al. Acute toxicity of postop-erative intensity-modulated radiotherapy and three-dimensional conformal radiotherapy for cervical cancer: The role of concomitant chemotherapy. J BUON 2019; 24(6): 2347‒54.
Hall EJ, Wuu CS. Radiation-induced second cancers: the im-pact of 3D-CRT and IMRT. Int J Radiat Oncol Biol Phys 2003; 56(1): 83‒8.
Zwahlen DR, Ruben JD, Jones P, Gagliardi F, Millar JL, Schneider U. Effect of intensity-modulated pelvic radiotherapy on sec-ond cancer risk in the postoperative treatment of endometrial and cervical cancer. Int J Radiat Oncol Biol Phys 2009; 74(2): 539‒45.
Tomasevic A, Plesinac Karapandzic V, Stojanovic Rundic S, Vuckovic S, Milinkovic P, Gavrilovic D, et al. 3D MRI-based evaluation of the 2D brachytherapy planning in patients with advanced cer-vical cancer: An analysis of the delivered dose. J BUON 2020; 25(1): 108‒15.